

Systemic Biological Therapy for Eczema

If eczema has not responded to standard topical therapies and falls into category of severe or very severe disease see flow chart below.

If the patient has **severe or very severe disease** – EASI score >21.1 and DLQI score >20 AND eczema has failed to respond to standard topical treatments, OR the person has a contraindication to or is intolerant of these treatments.

NICE has approved Dupilumab for the treatment of moderate to severe atopic dermatitis in adults, however as per this pathway it will only be used in HEY hospitals for those patients who fall into the severe or very severe classifications. Certain exceptions to this may be allowed if clinically appropriate and these individuals fall under the terms of the NICE guidance.

An adequate response is defined as: a 50% decrease in EASI score (EASI 50) AND at least a 4 point reduction in DLQI score from when treatment started

Choose the yellow or blue pathway depending on clinical appropriateness for individual patients:

